Vergoeding 2017-2021 voor ATC-subgroep B01AF : Directe remmers van factor xa
- Raming voor de totale Zvw-populatie
| 2017 | 2018 | 2019 | 2020 | 2021 | |
|---|---|---|---|---|---|
| B01AF01 Rivaroxaban (Xarelto ®) | 43.405.900 | 61.255.400 | 79.581.600 | 91.620.800 | 99.319.500 |
| B01AF02 Apixaban (Eliquis ®) | 31.311.200 | 46.041.300 | 61.322.400 | 76.708.900 | 92.040.500 |
| B01AF03 Edoxaban (Lixiana ®) | 5.111.300 | 11.379.000 | 17.799.400 | 23.596.200 | 27.326.300 |
| Totaal | 79.828.400 | 118.675.700 | 158.703.400 | 191.925.900 | 218.686.300 |